ProVerum Raises €68M for Novel Prostate Treatment
- Millions of men worldwide experience the frustrating symptoms of Benign Prostatic Hyperplasia (BPH), a non-cancerous enlargement of the prostate gland.
- The ProVerum stent isn't a drug; it's a minimally invasive implant designed to physically reshape the prostate.
- BPH affects approximately 50% of men aged 60 and over, and up to 90% of men by age 85, according to the National Institute of Diabetes and Digestive...
A New Approach to Benign Prostatic Hyperplasia: ProVerum’s Innovative Stent
Table of Contents
Millions of men worldwide experience the frustrating symptoms of Benign Prostatic Hyperplasia (BPH), a non-cancerous enlargement of the prostate gland. traditional treatments often involve medication or surgery, each with its own set of drawbacks. However, a new device developed by Irish medical technology company ProVerum is poised to offer a potentially superior alternative, reshaping the landscape of men’s health care.
How the ProVerum Stent Works
The ProVerum stent isn’t a drug; it’s a minimally invasive implant designed to physically reshape the prostate. Unlike medications that manage symptoms, or surgery that removes tissue, the stent works by gently compressing the prostate tissue, relieving pressure on the urethra and improving urine flow. This reshaping is achieved through a self-expanding stent, deployed via a standard cystoscope. The device aims to provide lasting relief while preserving sexual function, a common concern with existing treatments.
Outperforming Traditional Therapies?
ProVerum believes its device has the potential to outperform traditional BPH drug therapies,such as alpha-blockers and 5-alpha reductase inhibitors.These medications frequently enough come with side effects like dizziness, sexual dysfunction, and the need for long-term use. The stent, by addressing the physical obstruction, aims to provide a more durable solution with fewer ongoing complications. Clinical data, while still developing, suggests promising results in terms of symptom relief and improved quality of life for patients. The company is actively pursuing further clinical trials to solidify these findings.
global Investment and Go-to-Market strategy
The innovation has attracted notable investment from global sources, signaling confidence in its potential. New investors are actively influencing ProVerum’s go-to-market strategy, focusing on a phased rollout beginning in select European markets. This strategic approach allows for careful monitoring of clinical outcomes and refinement of the procedure before broader adoption. The influx of capital will also support expanded research and growth efforts, potentially leading to further advancements in the technology.
The Science Behind the Innovation
The development of the ProVerum stent is rooted in a deep understanding of prostate anatomy and the biomechanics of BPH. Researchers recognized that simply relieving the obstruction without altering the prostate’s structure offered limited long-term benefits. The stent’s design addresses this by applying controlled compression, effectively reshaping the prostate and creating a permanent channel for improved urine flow. This approach differs significantly from traditional surgical procedures like Transurethral Resection of the Prostate (TURP), which removes prostate tissue and can carry risks of bleeding and incontinence.
Looking Ahead
As of August 26, 2025, ProVerum is preparing for wider commercialization of its stent, with plans to expand into additional international markets. The company anticipates that this innovative device will offer a valuable new option for men seeking relief from BPH, potentially transforming the way this common condition is managed.Continued research and clinical validation will be crucial to fully realizing the stent’s potential and establishing its long-term efficacy and safety.
Our goal is to provide men with a lasting solution to BPH that improves their quality of life without the side effects and limitations of traditional